Stifel Keeps ClearPoint Neuro at Buy, Cuts Target to $18
Stifel maintained its Buy rating on ClearPoint Neuro and lowered its price target to $18 from $22.
Related stories
RBC Expects Estee Lauder Fiscal Q1 Results to Meet Consensus
RBC expects Estee Lauder to meet consensus for fiscal Q1 results.
M impact | EQUITY | Oct 29, 2026, 04:23 PM UTC
Noel Tata Retires as Trent Chairman, to Leave Five Other Boards Nov. 12
Tata has retired as chairman of Trent Limited and is due to step down from the boards of five other group companies on Nov. 12, under the group’s age-related retirement policies. H
M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC
Adani Group and IHCL to Develop Eight Airport Hotels
The partnership will add 2,000 rooms across brands over the next 3–4 years at airports in Mumbai, Ahmedabad, Lucknow and Guwahati.
M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC
Milky Mist Q2 Revenue Rises 42% to ₹1,089 Crore; Profit Nearly Triples
Milky Mist Dairy Food reported record quarterly revenue for Q2FY27, with net profit at ₹78 crore. Revenue from operations, gross profit and EBITDA also reached quarterly highs.
M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC
Canada Takes Stake in Cohere as Cohere Opens a Funding Round
The Canadian government acquired a stake in Cohere as the AI company opened a funding round.
L impact | EQUITY | Oct 29, 2026, 04:22 PM UTC
Ottawa Acquires Stake in Cohere as AI Firm Starts a Funding Round
The Canadian government acquired a stake in Cohere as the AI company began a funding round.
M impact | EQUITY | Oct 29, 2026, 04:22 PM UTC